Anónimo. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. U.S. Food and Drug Administration 2019:13 de diciembre. [Ref.ID 103231]

Shah R, Khan B, Latham SB, Khan SA, Rao SB. A meta-analysis of aspirin for the primary prevention of cardiovascular diseases in the context of contemporary preventive strategies. Am J Med 2019:31 de mayo. [Ref.ID 103205]

Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]

Byrne P, Cullinan J, Smith S. Statins for primary prevention of cardiovascular disease. BMJ 2019;367:16 de octubre. [Ref.ID 103197]

Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]

Xie Y, Bowe B, Yan Y, Xian H, Li T. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365:30 de mayo. [Ref.ID 103138]

Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, Heianza Y, Qi L. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ 2019;365:l1628. [Ref.ID 103121]

Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019:15 de abril. [Ref.ID 103087]

Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019;365:9 de abril. [Ref.ID 103085]

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42:abril. [Ref.ID 103082]

Zhong VW, Van Horn L, Cornelis MC, Wilkins JT, Ning H, Carnethon MR, Greenland P, Mentz RJ, Tucker KL, Zhao L, Norwood AF, Lloyd-Jones DM, Allen NB. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA 2019;321:19 de marzo. [Ref.ID 103072]

Anónimo. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). U.S. Food and Drug Administration 2019:21 de febrero. [Ref.ID 103045]

Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events. A systematic review and meta-analysis. JAMA 2019;321:22 de enero. [Ref.ID 103021]

Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:2 de febrero. [Ref.ID 103016]

Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, for the VITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019;380:3 de enero. [Ref.ID 102995]

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:3 de enero. [Ref.ID 102994]

Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]

Dehghan M, Mente A, Rangarajan S, Sheridan P, Mohan V, Iqbal R, Gupt R, Lear S, Wentzel-Viljoen E, Avezum A, López-Jaramillo P, Mony P, Varma RP, Kumar R, Chifamba J, Alhabib KF, Mohammadifard N, Oguz A, Lanas F, Rozanska D, Bostrom KB, Yusoff K, Tsolkile LP, Dans A, Yusufali A, Orlandini A, Poirier P, Khatib R, Hu B, Wei L, Yin L, Deeraili A, Yeates K, Yusuf R, Ismail N, Mozaffarian D, Teo K, Anand SS, Yusuf S, on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2018;392:24 de noviembre. [Ref.ID 102854]

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2018:9 de noviembre. [Ref.ID 102850]